Business Wire

‘The Nest’ by Webhelp expands across Europe

Share

The leading global customer experience (CX) and business solutions provider, Webhelp has announced the expansion of its program, The Nest by Webhelp, across Europe which aims to support startups and scaleups to provide the best-in-class customer experience. The Nest enables fast-growing companies across all sectors to grow exponentially by offering a unique, tailor-made outsourced CX proposition.

This news comes at a time when many young companies are facing multiple challenges due to the pandemic and are requiring flexibility and ROI optimization while uncertainly prevails in their business environments.

Chloe de Mont-Serrat, Head of The Nest, said: “We’re delighted to expand our offering to companies across Europe. Thriving startups have one key thing in common - exceptional customer experience. Outsourcing CX with a trusted partner can enable businesses to scale up quickly while maximizing ROI, freeing them up to focus on what matters most - growing their business.”

Launched in France in 2018, the program already supports dozens of the most dynamic startups, many of which have been placed highly in The French Tech Next rankings. In addition to this, Webhelp is a long-standing partner for countless unicorn startups and is well-placed to help fast-growth companies differentiate their businesses. The program is taking on a European dimension by expanding into the UK, Spain, Germany, The Nordics, The Netherlands, and Turkey.

“We’re excited to launch The Nest in the Nordics to help local startups build an exceptional customer experience. We understand that startups face many complex challenges during the early stages of growth, from developing expertise and processes to support long-term growth to expanding rapidly in new markets and building innovative products and services to differentiate from the competition,” added Victor Sundén, Chief Commercial Officer, The Nest, Nordics.

The Nest by Webhelp makes the expertise of Webhelp, the European market leader for CX, available to smaller businesses and is based on a strong people-first working culture. Its core focus is to support its clients as they grow their businesses and enable them to generate competitive advantages in the CX space. The program offers a wide variety of services, all of which can be customized to the client’s individual needs, including, but not limited to; omnichannel customer engagement services (including customer care, community management and technical support), sales support (customer acquisition & retention, sales assistance) and digital services (content management, moderation services, digital marketing). The program operates 24 hours a day, seven days a week and is available in more than 40 languages.

In addition to a best-in-class customer experience delivered by expert teams, clients also get access to ‘The Nest Community.' This resource will offer members mentoring, business development, and networking opportunities as an additional way to generate traction and achieve better results through a strategic startup network.

As Charles Egly, CEO of Younited Credit, and one of the first startups to join The Nest by Webhelp program, testified: "In the early days of a startup, the senior team often try to tackle all the issues head-on, sometimes to the detriment of the final product or service. The outsourced support that The Nest program offers was invaluable to expand our team and provide reinforced expertise. It also allowed us to conquer new markets much faster. Working with an outsourced partner in this way offers increased efficiency, lower operating costs, more flexibility, and faster time-to-market. Not to mention, access to the best processes and tools on the market, most of which are usually too costly for a startup.”

Webhelp Co-Founder, Olivier Duha, concluded: "We are thrilled that - despite the COVID-19 pandemic - the startup world is still booming, and the pace of fundraising has not slowed down. Ultimately, supporting fast growing startups has always been in our DNA, as we still have an entrepreneurial culture that perfectly guides that.”

END

About The Nest

The Nest by Webhelp is an outsourced customer experience (CX) program by Webhelp to help startups and fast-growth companies differentiate themselves and scale-up their team, quickly and simply. Operating across Europe, the program provides clients access to its global network of operational customer experience specialists 365 days a year and seven days a week. The Nest offers a wide variety of services, all of which are customized to the client’s individual needs, including, but not limited to; omnichannel customer engagement services (including customer care, community management and technical support), sales support (customer acquisition & retention, sales assistance) and digital services (content management, moderation services, digital marketing). Clients of The Nest will have access The Nest Community, offering mentoring and other business support and guidance to enable startups to grow and succeed in their marketplace.

More information can be found at thenest.webhelp.com

About Webhelp

Making business more human for the world’s most exciting brands

We live in an era of fast connectivity and AI. Today, human experiences have even more power to make businesses come to life in customers’ hearts and minds. Webhelp is committed to making business more human. It’s through this commitment that Webhelp enriches customer experience, and designs business solutions that create value for the world’s most exciting companies. Webhelp is a partner across a range of services including customer experience solutions, social media moderation through to payment services. Hundreds of brands across the world trust Webhelp because of their people, the culture they work in, and the ideas and technology they put to work. Webhelp believes that Emotional Intelligence creates a lasting impact, and their skill in marrying a differentiating human touch to the right technology is what makes a real difference for their clients. By choosing Webhelp they access the passion and experience of more than 75,000 game-changers from more than 150 locations in over 50 countries. Each one determined to bring their own intelligence, empathy and experience to the table every day. Webhelp invests in people and the environment they work in, because they know that when people thrive, it has a powerful impact on them, their customers and on their partners’ business. Webhelp believes that making business more human leads to a better customer experience - and a healthier bottom line. Webhelp is the European leader in their industry, with a revenue of more than €1,6B in 2020, and aims for a global leadership position. Webhelp is currently owned by its management and GBL, a leading global investment holding, as of November 2019.

More information can be found at www.webhelp.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACTS:
Holly Pither
Holly@tribepr.co.uk
+44 (0)7961 088 878

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye